Phase I Clinical Trial of Paclitaxel Plus Ifosfamide for the Patients with Refractory Ovarian Cancer / 대한암학회지
Journal of the Korean Cancer Association
;
: 895-903, 2000.
Article
in Korean
| WPRIM
| ID: wpr-24519
ABSTRACT
PURPOSE:
Patients with advanced ovarian carcinoma and refractory to platinum based chemotherapy have a very poor prognosis and effective salvage regimens are needed. This study was conducted in order to determine the maximum tolerated dose (MTD) and dose limiting toxicity of combination with paclitaxel and ifosfamide. MATERIALS ANDMETHODS:
After premedication, patients received paclitaxel (110~225 mg/m2) as a 24 hour IV infusion on day 1. Ifosfamide (1,000~1,500 mg/m2) was given as a 12 hour IV infusion with standard dose of mesna on day 2~6. All patients received G-CSF (granulocyte colony stimulating factor) on day 6~15.RESULTS:
12 patients with advanced ovarian cancer entered this trial. Toxicity included bone marrow suppression, neuromuscular toxicity, urothelial toxicity, gastrointestinal toxicity, which occurred in 84.6%, 65.3%, 30.7%, 88.4% of cycles.CONCLUSION:
Neuromuscular toxicity was dose limiting toxicity. Maximum tolerated dose in com bination with paclitaxel and ifosfamide was 175 mg/m2 of paclitaxel and 1,500 mg/m2 of ifosfamide.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ovarian Neoplasms
/
Platinum
/
Premedication
/
Prognosis
/
Bone Marrow
/
Granulocyte Colony-Stimulating Factor
/
Mesna
/
Paclitaxel
/
Maximum Tolerated Dose
/
Drug Therapy
Type of study:
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Cancer Association
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS